Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: A randomized multicenter phase III clinical trial - SAKK 44/00-CECOG/PAN.1.3.001

Journal of Clinical Oncology

Volumn 26, Issue 22, 2008, Pages 3695-3701

  Bernhard, Jürg ^a   Dietrich, Daniel ^b   Scheithauer, Werner ^b   Gerber, Daniela ^b   Bodoky, György ^b   Ruhstaller, Thomas ^b   Glimelius, Bengt ^b   Bajetta, Emilio ^b   Schüller, Johannes ^b   Saletti, Piercarlo ^b   Bauer, Jean ^b   Figer, Arie ^b   Pestalozzi, Bernhard C ^b   Köhne, Claus Henning ^b   Mingrone, Walter ^b   Stemmer, Salomon M ^b   Tàmas, Karin ^b   Kornek, Gabriela V ^b   Koeberle, Dieter ^b   Herrmann, Richard ^b  

^a IBCSG Coordinating Center   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CAPECITABINE; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INFUSION; DRUG USE; FEMALE; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; PAIN; PANCREAS ADENOCARCINOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT FAILURE; WEIGHT; ADENOCARCINOMA; BODY WEIGHT; DRUG ADMINISTRATION; DRUG EFFECT; EUROPE; INFUSION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PAIN ASSESSMENT; PANCREAS TUMOR; PATHOLOGY; PROSPECTIVE STUDY;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY WEIGHT; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, PARENTERAL; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; QUALITY OF LIFE; TIME FACTORS; TREATMENT FAILURE;

EID: 49249108437     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.6240     Document Type: Article

References (30)

1. Herrmann R, Bodoky G, Ruhstaller T, et al: Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: A randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25:2212-2217, 2007
2. Rothenberg ML, Moore MJ, Cripps MC, et al: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7:347-353, 1996
3. Burris HA 3rd, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
4. Colucci G, Giuliani F, Gebbia V, et al: Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: A prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 94:902-910, 2002
5. Reni M, Cordio S, Milandri C, et al: Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: A randomised controlled multicentre phase III trial. Lancet Oncol 6:369-376, 2005
6. Verweij J: The benefit of clinical benefit: A European perspective. Ann Oncol 7:333-334, 1996
7. Gelber RD: Gemcitabine for pancreatic cancer: How hard to look for clinical benefit? An American perspective. Ann Oncol 7:335-337, 1996
8. Hoffman K, Glimelius B: Evaluation of clinical benefit of chemotherapy in patients with upper gastrointestinal cancer. Acta Oncol 37:651-659, 1998
9. Richards DA, Boehm KA, Waterhouse DM, et al: Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: Results of a phase II randomized, double-blind, placebo-controlled, multicenter study. Ann Oncol 17:1096-1102, 2006
10. Haddock MG, Swaminathan R, Foster NR, et al: Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: Results of the North Central Cancer Treatment Group Phase II Study N9942. J Clin Oncol 25:2567-2572, 2007
11. Bramhall SR, Schulz J, Nemunaitis J, et al: A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87:161-167, 2002
12. Heinemann V, Quietzsch D, Gieseler F, et al: Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24:3946-3952, 2006
13. Moore MJ, Hamm J, Dancey J, et al: Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21:3296-3302, 2003
14. Van Cutsem E, van de Velde H, Karasek P, et al: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430-1438, 2004
15. Bernhard J, Maibach R, Thurlimann B, et al: Patients' estimation of overall treatment burden: Why not ask the obvious? J Clin Oncol 20:65-72, 2002
16. Butow P, Coates A, Dunn S, et al: On the receiving end: IV - Validation of quality of life indicators. Ann Oncol 2:597-603, 1991
17. Hurny C, Bernhard J, Coates A, et al: Responsiveness of a single-item indicator versus a multiitem scale: Assessment of emotional well-being in an international adjuvant breast cancer trial. Med Care 34:234-248, 1996
18. Hurny C, Bernhard J, Bacchi M, et al: The Perceived Adjustment to Chronic Illness Scale (PACIS): A global indicator of coping for operable breast cancer patients in clinical trials - Swiss Group for Clinical Cancer Research (SAKK) and the International Breast Cancer Study Group (IBCSG). Support Care Cancer 1:200-208, 1993
19. Bernhard J, Hurny C, Maibach R, et al: Quality of life as subjective experience: Reframing of perception in patients with colon cancer undergoing radical resection with or without adjuvant chemotherapy - Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 10:775-782, 1999
20. Roth AD, Fazio N, Stupp R, et al: Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: A randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 25:3217-3223, 2007
21. Borner MM, Bernhard J, Dietrich D, et al: A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: Efficacy, quality-of-life and toxicity. Ann Oncol 16:282-288, 2005
22. Zabora J, BrintzenhofeSzoc K, Curbow B, et al: The prevalence of psychological distress by cancer site. Psychooncology 10:19-28, 2001
23. Bernhard J, Sullivan M, Hurny C, et al: Clinical relevance of single item quality of life indicators in cancer clinical trials. Br J Cancer 84:1156-1165, 2001
24. Fishman B, Pasternak S, Wallenstein SL, et al: The Memorial Pain Assessment Card: A valid instrument for the evaluation of cancer pain. Cancer 60:1151-1158, 1987
25. Sloan JA, Dueck A: Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials. J Biopharm Stat 14:73-96, 2004
26. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007
27. Fayers P: MRC quality of life studies using a daily diary card: Practical lessons learned from cancer trials. Qual Life Res 4:343-352, 1995
28. Fitzsimmons D, George S, Payne S, et al: Differences in perception of quality of life issues between health professionals and patients with pancreatic cancer. Psychooncology 8:135-143, 1999
29. Fitzsimmons D, Johnson CD, George S, et al: Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer: EORTC Study Group on Quality of Life. Eur J Cancer 35:939-941, 1999
30. Yount S, Cella D, Webster K, et al: Assessment of patient-reported clinical outcome in pancreatic and other hepatobiliary cancers: The FACT Hepatobiliary Symptom Index. J Pain Symptom Manage 24:32-44, 2002